BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE and CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Overview

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is the #11 most commonly reported adverse reaction for BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, manufactured by AstraZeneca Pharmaceuticals LP. There are 3,977 FDA adverse event reports linking BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE to CHRONIC OBSTRUCTIVE PULMONARY DISEASE. This represents approximately 1.7% of all 236,943 adverse event reports for this drug.

Patients taking BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE who experience chronic obstructive pulmonary disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is a less commonly reported adverse event for BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, but still significant enough to appear in the safety profile.

Other Side Effects of BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE

In addition to chronic obstructive pulmonary disease, the following adverse reactions have been reported for BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE:

• DYSPNOEA — 17,377 reports
• ASTHMA — 11,764 reports
• COUGH — 7,696 reports
• DRUG INEFFECTIVE — 6,635 reports
• OFF LABEL USE — 5,796 reports
• PNEUMONIA — 5,628 reports
• WHEEZING — 5,600 reports
• FATIGUE — 5,276 reports
• MALAISE — 4,510 reports
• HEADACHE — 4,437 reports

Other Drugs Associated with CHRONIC OBSTRUCTIVE PULMONARY DISEASE

The following drugs have also been linked to chronic obstructive pulmonary disease in FDA adverse event reports:

Does BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE cause CHRONIC OBSTRUCTIVE PULMONARY DISEASE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE has been reported as an adverse event in 3,977 FDA reports for BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is CHRONIC OBSTRUCTIVE PULMONARY DISEASE with BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE accounts for approximately 1.7% of all adverse event reports for BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, making it a notable side effect.

What should I do if I experience CHRONIC OBSTRUCTIVE PULMONARY DISEASE while taking BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE?

If you experience chronic obstructive pulmonary disease while taking BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages